ManageEngine Launches New Data Centers in Canada, Offering Enhanced Data Security and Privacy to Regional Customers
Opening of Data Centers in Toronto and Montreal Signify Company’s Commitment and Investment in the…
Month: January 2023
Smith Micro Executes New Digital Family Safety Contract with Tier 1 U.S. Mobile Network Operator
PITTSBURGH–(BUSINESS WIRE)–$SMSI #SaaS–(Nasdaq: SMSI), Smith Micro Software, Inc., today announced that the Company has entered…
Veeam Research Finds IT Leaders Feel Increasingly Unprotected from Cyberattacks and Other Disasters
Veeam Data Protection Trends Report 2023 shows that data backup budgets will continue to rise…
GrammaTech and T.E.N. Announce Winner of First Annual Product Security Executive of the Year Award
Jason Christman, Vice President and Chief Product Security Officer for Johnson Controls Recognized for Making…
Assertio Announces Partnership with the Lennox-Gastaut Syndrome (LGS) Foundation
SYMPAZAN® (clobazam) oral film from Assertio is used for the adjunctive treatment of seizures associated…
Israel-Based Clearmind Announces Additional Positive Results from the Third Part of its Pre-Clinical Study for Cocaine Addiction Treatment
The results of pre-clinical in-vivo research studies suggested that Clearmind’s drug candidate MEAI may be…
AIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical Center
Research collaboration will evaluate the potential of AIM’s Ampligen® (rintatolimod) in combination with AstraZeneca’s Imfinzi…
Neuronetics Announces Data Confirming Efficacy in Treating Anxious Depression with NeuroStar® Advanced Therapy for Mental Health
Peer-reviewed publication shows NeuroStar TMS as an effective non-drug treatment for depression with comorbid anxiety…
Checkpoint Therapeutics to Participate in the B. Riley Securities’ 3rd Annual Oncology Conference
WALTHAM, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a…
Blue Water Vaccines Announces Appointment of Seasoned Public Market and Private Equity Investment Leader Timothy Ramdeen to Board of Directors
CINCINNATI, Jan. 17, 2023 (GLOBE NEWSWIRE) — Blue Water Vaccines Inc. (“BWV” or “Blue Water…
CorMedix Inc. Announces Promotions in Commercial and Tech Ops
BERKELEY HEIGHTS, N.J., Jan. 17, 2023 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical…
SciSparc Announces Additional Positive Results from the Third Part of Clearmind Medicine Inc. Pre-Clinical Study for Cocaine Addiction Treatment
The results of pre-clinical in-vivo research studies suggested that Clearmind’s drug candidate MEAI may be…
Mustang Bio to Participate in the B. Riley Securities’ 3rd Annual Oncology Conference
WORCESTER, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (“Mustang” or the “Company”)…
Aeterna Zentaris Provides Business Update and Outlines Key Upcoming Milestones
Aeterna Zentaris focused on accelerating recruitment for ongoing DETECT trial and efforts to partner rights…
Shockwave Medical Announces Agreement to Acquire Neovasc
Neovasc’s Innovative Reducer System Will Target the Estimated $5 Billion Refractory Angina Market Shockwave Medical…
Theriva Biologics Announces First Patient Dosed in VIRAGE, a Phase 2b Trial of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma
-Initiation of Phase 2b trial follows clearance from the US Food and Drug Administration (FDA)…
NewAmsterdam Announces Positive Results from ROSE2, Phase 2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy
— Achieved primary endpoint with statistically significant reduction in LDL-C (p < 0.0001) —— Median…
Idera Pharmaceuticals Announces Name Change to Aceragen, Inc. and Provides Near-Term Strategic Outlook
Company completes preferred stock conversion, implements reverse stock split, and regains Nasdaq compliance Company positioned…
Biomea Fusion Doses First Patient in Phase I/Ib Clinical Trial (COVALENT-102) of BMF-219 in KRAS Mutant Solid Tumors
BMF-219 is the first menin inhibitor to be clinically studied in patients with KRAS-mutated non-small…
Oncotelic Announces the launch of PDAO token
– PDAO is to Revolutionize Decentralized Autonomous Organization (DAO) AGOURA HILLS, Calif., Jan. 17, 2023…